Vivos Therapeutics, Inc. (VVOS)
NASDAQ: VVOS · IEX Real-Time Price · USD
2.450
-0.120 (-4.67%)
At close: Jul 19, 2024, 4:00 PM
2.050
-0.400 (-16.33%)
Pre-market: Jul 22, 2024, 4:21 AM EDT
Vivos Therapeutics Revenue
Vivos Therapeutics had revenue of $13.36M in the twelve months ending March 31, 2024. Revenue in the quarter ending March 31, 2024 was $3.42M. In the year 2023, Vivos Therapeutics had annual revenue of $13.80M.
Revenue (ttm)
$13.36M
Revenue Growth
-17.70%
P/S Ratio
0.62
Revenue / Employee
$108,642
Employees
123
Market Cap
8.32M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 13.80M | -2.22M | -13.87% |
Dec 31, 2022 | 16.02M | -861.00K | -5.10% |
Dec 31, 2021 | 16.89M | 3.82M | 29.23% |
Dec 31, 2020 | 13.07M | 1.67M | 14.68% |
Dec 31, 2019 | 11.39M | 7.60M | 200.43% |
Dec 31, 2018 | 3.79M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Molecular Templates | 31.76M |
iCoreConnect | 9.03M |
Syra Health | 6.08M |
Kineta | 5.16M |
Organovo Holdings | 109.00K |
Bionomics | 15.00K |
VVOS News
- 25 days ago - Vivos Therapeutics Announces Positive Results From 7-Month Multi-Site Pilot of its New Provider-Based Marketing and Distribution Model - GlobeNewsWire
- 5 weeks ago - Vivos Therapeutics Closes $7.5 Million At-The-Market Private Equity-Backed Investment and Launches Strategic Marketing and Distribution Alliance - GlobeNewsWire
- 2 months ago - Vivos Therapeutics Reports First Quarter 2024 Financial Results and Provides Operational Update - GlobeNewsWire
- 2 months ago - Vivos Therapeutics Schedules Release of First Quarter 2024 Financial Results and Conference Call - GlobeNewsWire
- 3 months ago - Vivos Therapeutics' Flagship CARE Oral Medical Devices Receive Full Approval for Medicare Reimbursement - GlobeNewsWire
- 4 months ago - Vivos Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Operational Update - GlobeNewsWire
- 4 months ago - Vivos Therapeutics Schedules Release of Fourth Quarter and Full Year 2023 Financial Results and Conference Call - GlobeNewsWire
- 5 months ago - Vivos Therapeutics Highlights Significant Favorable Market Developments Creating Exciting New Growth Opportunities - GlobeNewsWire